Medicare Enrolled
Dr. Jeffrey Freeman, D.O.
Endocrinology · Philadelphia, PA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Freeman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Freeman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Freeman
Dr. Jeffrey Freeman is an endocrinology specialist in Philadelphia, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Freeman performed 1,476 Medicare services across 807 unique beneficiaries.
Between the years covered by Open Payments, Dr. Freeman received a total of $300,875 from 73 pharmaceutical and/or device companies across 1422 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Freeman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 23% volume in PA
$300,875 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,476
Medicare services
Top 23% in PA for endocrinology
807
Unique beneficiaries
$82
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~74 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
680 | $98 | $196 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
276 | $41 | $65 |
| Continuous glucose monitoring with interpretation This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results. |
123 | $27 | $100 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
107 | $107 | $175 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
100 | $71 | $141 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
65 | $65 | $90 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
63 | $147 | $247 |
| Continuous glucose monitoring, sensor under skin This procedure involves continuous monitoring of blood sugar levels in tissue fluid using a sensor placed under the skin with provider-supplied equipment. |
34 | $113 | $361 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
28 | $125 | $255 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$300,875
Total received (2018-2024)
Avg $42,982/year across 7 years
Top 4% in PA for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
73
Companies
1,422
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$265,747 (88.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$19,191 (6.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,938 (5.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$9,841
2023
$23,703
2022
$36,588
2021
$19,639
2020
$28,695
2019
$88,918
2018
$93,491
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$6,720
Mannkind Corporation
$791
Medtronic, Inc.
$419
Lilly USA, LLC
$391
Amgen Inc.
$260
Abbott Laboratories
$206
ABBVIE INC.
$119
Bayer Healthcare Pharmaceuticals Inc.
$97
Novartis Pharmaceuticals Corporation
$85
Boehringer Ingelheim Pharmaceuticals, Inc.
$81
Dexcom, Inc.
$76
AGEPHA Pharma FZ LLC
$64
Chiesi USA, Inc.
$60
Kyowa Kirin, Inc.
$55
SANOFI-AVENTIS U.S. LLC
$50
Ascensia Diabetes Care Us Inc.
$47
PFIZER INC.
$42
Astellas Pharma US Inc
$36
Radius Health, Inc.
$30
Amphastar Pharmaceuticals, Inc.
$29
Alexion Pharmaceuticals, Inc.
$28
Averitas Pharma Inc.
$25
Xeris Pharmaceuticals, Inc.
$22
OPKO Pharmaceuticals, LLC
$19
Corcept Therapeutics
$19
IBSA Pharma Inc.
$19
Tandem Diabetes Care, Inc.
$17
Esperion Therapeutics, Inc.
$15
CeQur Corporation
$11
BETA BIONICS, INC.
$10
Top 3 companies account for 80.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novo Nordisk Inc
$149,227
Amarin Pharma Inc.
$43,751
Amgen Inc.
$26,342
Valeritas, Inc.
$16,674
Boehringer Ingelheim Pharmaceuticals, Inc.
$16,521
Bayer HealthCare Pharmaceuticals Inc.
$11,695
Bayer Healthcare Pharmaceuticals Inc.
$9,827
AstraZeneca Pharmaceuticals LP
$6,831
SANOFI-AVENTIS U.S. LLC
$4,103
Mannkind Corporation
$3,113
Lilly USA, LLC
$3,083
MannKind Corporation
$978
Medtronic, Inc.
$948
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$891
Merck Sharp & Dohme Corporation
$578
Abbott Laboratories
$509
Corcept Therapeutics
$455
Xeris Pharmaceuticals, Inc.
$374
Medtronic MiniMed, Inc.
$325
Becton, Dickinson and Company
$304
Novartis Pharmaceuticals Corporation
$267
Dexcom, Inc.
$249
ABBVIE INC.
$226
Esperion Therapeutics, Inc.
$199
Zealand Pharma US, Inc.
$196
Shire North American Group Inc
$195
CeQur Corporation
$165
Takeda Pharmaceuticals U.S.A., Inc.
$160
Horizon Therapeutics plc
$160
Alexion Pharmaceuticals, Inc.
$149
Tandem Diabetes Care, Inc.
$148
OPKO Pharmaceuticals, LLC
$133
Amneal Pharmaceuticals LLC
$108
Regeneron Pharmaceuticals, Inc.
$107
Bigfoot Biomedical Inc
$106
PFIZER INC.
$104
Intuity Medical Inc
$101
Ipsen Biopharmaceuticals, Inc
$101
Radius Health, Inc.
$85
Ultragenyx Pharmaceutical Inc.
$81
Kyowa Kirin, Inc.
$78
Ascensia Diabetes Care Us Inc.
$76
Janssen Pharmaceuticals, Inc
$74
Regeneron Healthcare Solutions, Inc.
$74
Amphastar Pharmaceuticals, Inc.
$73
IBSA Pharma Inc.
$67
Merck Sharp & Dohme LLC
$64
AGEPHA Pharma FZ LLC
$64
Chiesi USA, Inc.
$60
AbbVie, Inc.
$59
AbbVie Inc.
$58
LifeScan, Inc.
$50
EISAI INC.
$47
Currax Pharmaceuticals LLC
$46
Ascendis Pharma Inc
$43
Sun Pharmaceutical Industries Inc.
$40
Astellas Pharma US Inc
$36
Clarus Therapeutics Inc.
$35
Acerus Pharmaceuticals Corporation
$28
Mallinckrodt Hospital Products Inc.
$27
Averitas Pharma Inc.
$25
DEXCOM, INC.
$20
RECORDATI_RARE_DISEASES_INC.
$19
Janssen Biotech, Inc.
$18
Amryt Pharma Holdings Ltd
$17
Aytu BioScience, Inc
$16
UCB, Inc.
$15
Tolmar, Inc.
$14
Hikma Pharmaceuticals USA
$13
Insulet Corporation
$13
Retrophin, Inc.
$13
Teva Pharmaceuticals USA, Inc.
$12
BETA BIONICS, INC.
$10
Top 3 companies account for 72.9% of all-time payments
Associated products mentioned in payments ›
(820) Cholbam · ACTHAR · AFREZZA · AJOVY · APRISO · AVSOLA · Androgel · BAQSIMI · BD NANO · BD Nano · BD Nano 2nd Gen Pen Needle · Belviq · CONTRAVE · CYCLOSET · CeQur Simplicity · Cimzia · Corlanor · Crysvita · Cryvista · DEXCOM CGM · DEXCOM G6 TRANSMITTER · DIABETES - DISEASE · Dexcom CGM · Dexcom G6 Transmitter · ELAPRASE · ENTRESTO · EVENITY · EVERSENSE 365 SENSOR KIT (RETAIL) · EVERSENSE E3 SENSOR KIT - RETAIL · EVERSENSE E3 SMART TRANSMITTER KIT · FARXIGA · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre 2 · FreeStyle Libre blood glucose Flash Monitoring System · GUARDIAN SENSOR (3) · GVOKE HYPOPEN · GVOKE PFS · HUMALOG · HUMULIN · INPEN SMART INSULIN DELIVERY SYSTEM · INVOKANA · InPen · JANUVIA · JARDIANCE · JATENZO · Kerendia · Korlym · LEQVIO · LODOCO · Levemir · MINIMED 770G · MINIMED 780G · MOUNJARO · MYCAPSSA · Macrilen · Minimed 670G System · Minimed 770G System · Mitigare · NATPARA · NATPARA (PARATHYROID HORMONE) · NEXLETOL · NO PRODUCT DISCUSSED · Natesto · Norditropin · OT Verio Reflect "One Touch Meter and Strips" · Omnipod · OneTouch · Ozempic · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Pogo Automatic Blood Glucose Monitoring System · Prolia · QUTENZA · RAYALDEE · RECORLEV · RIOMET ER · RYBELSUS · Rayaldee · Repatha · Rybelsus · SIGNIFOR LAR · SOLIQUA · SOLIQUA 100/33 · SOMATULINE DEPOT · SOMAVERT · STEGLATRO · STRENSIQ · SYNTHROID · Saxenda · Sogroya · Somatuline Depot · Strensiq · Synthroid · TEPEZZA · TOUJEO · TRADJENTA · TREMFYA · TRULICITY · TZIELD · Tirosint · Tresiba · Tymlos · UNITHROID · UNITY DIABETES MANAGEMENT SYSTEM · V-GO · V-GO DISPOSABLE INSULIN DELIVERY · Vascepa · Veozah · Victoza · Wegovy · XARELTO · Xultophy 100/3.6 · ZEGALOGUE · iLet Bionic Pancreas · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ · t:slim X2 insulin pump
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (88%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for endocrinology in PA.
Geographic Context
Endocrinologists within 10 mi
202
Per 100K population
12.8
County median income
$60,698
Nearest hospital
BELMONT BEHAVIORAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Freeman is a clinical cardiology specialist, with above-average Medicare volume (top 23% in PA), with speaking/promotional industry engagement in the top 4% of PA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Freeman experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Freeman performed 680 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Freeman receive payments from pharmaceutical companies?
Yes. Dr. Freeman received a total of $300,875 from 73 companies across 1,422 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Freeman's costs compare to other endocrinologists in Philadelphia?
Dr. Freeman's average Medicare payment per service is $82. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Freeman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Endocrinology
Common procedures, typical costs, and what industry payments mean in endocrinology.
Same specialty & city
Endocrinologists in Philadelphia
Browse endocrinologists in Philadelphia ranked by procedure volume and transparency data.
Highest volume
Top Endocrinologists in PA
Endocrinologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Endocrinologists in PA
Which PA endocrinologists receive the most from drug and device companies.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
By company
Amarin Pharma Inc. Payments to Doctors
See all physicians who received payments from Amarin Pharma Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology